RLA-4842

Cat. No.:	HY-152512
Molecular Formula:	$C_{42}H_{46}F_3N_5O_8S$
Molecular Weight:	837.9
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line[1].
In Vitro	RLA-4842 (compound 9) (0-25 μM; 10 min) inhibits LNCaP-AR cells proliferation with concentration-dependent manner[1]. RLA-4842 (5 μM; 0-6 d) shows inhibitory for VCaP, PC3, LNCaP and C4-2B cells proliferation[1]. RLA-4842 (5 μM; 24 h) down-regulates the expression level of KLK-2 and KLK-3 in LNCaP cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	VCaP, PC3, LNCaP and C4-2B cells.
Concentration:	0, 0.1, 0.5, 1, 5, 10, 20 or 25 μM.
Incubation Time:	0-6 d.
Result:	Showed antiproliferative effect.

REFERENCES

[1]. Gonciarz RL, et al. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Jan 14;249:115110.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA